Cure My Disease

Don't miss your cure!

 Log in / Sign up

New trazodone formula tested for similarity to current version

NCT ID NCT06773767

Completed Knowledge-focused Sponsor: Aziende Chimiche Riunite Angelini Francesco S.p.A Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a new polymer version of the antidepressant trazodone (150 mg and 300 mg tablets) is absorbed in the body the same way as the current Contramid® version. Sixty-four healthy adults took both forms in a crossover design to measure drug levels in the blood. The goal was to see if the new version is bioequivalent, meaning it could be used as an alternative.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
trazodone hydrochloride
What this could lead to
If successful, this could show that the new polymer version of trazodone works just as well as the current one, potentially offering a more affordable or easier-to-manufacture option.
What could go wrong
This is an early-stage study in healthy volunteers, not patients. It only checks how the drug is absorbed, not if it works better or has fewer side effects. The results may not apply to people with depression or anxiety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOAVAILABILITY HEATHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIOAVAILABILITY HEATHY VOLUNTEERS BIOAVAILABILITY STUDY BIOEQUIVALANCE

Contacts and locations

Locations

  • SocraTec R&D GmbH Clinical Pharmacology

    Erfurt, Germany, 99084, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.